Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 13;13:1545–1556. doi: 10.2147/PPA.S215037

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Brixner et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Study sample selection.

Notes: ^aDirect feed claims consisted of filled claims only and were excluded from abandonment analysis. The following treatments were included: etanercept, infliximab, certolizumab, golimumab, anakinra, tocilizumab, secukinumab, ixekizumab, ustekinumab, abatacept, rituximab, natalizumab, vedolizumab, tofacitinib, and apremilast. ^bClaims with government-provided insurance were excluded as these patients were prohibited from using all components of the PSP. ^cDetermined using all available claims from 1/1/2006 to the index date. ^dAutoimmune diseases included rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, and uveitis.

Abbreviations: ADA, adalimumab; AS, ankylosing spondylitis; HS, hidradenitis suppurativa; IBD, inflammatory bowel disease; PsA, psoriatic arthritis; PsO, psoriasis; PSP, patient support program; RA, rheumatoid arthritis; UV, uveitis.